NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy. As the therapeutic arsenal for relapsed/refractory multiple ...

Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in PD-L1 CPS ≥1 disease. Overall survival was not improved at 21.3 ...

Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...

FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...

Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.

Building on her discovery of the GLP-1 signaling pathway's role in sarcoma biology, Erica Pimenta, MD, PhD, of the Dana-Farber Cancer Institute, is exploring the therapeutic poten ...

In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...

Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month outcomes among patients achieving complete response. Safety signals aligned with ...

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...

The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...

The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategi ...